Pseudohypoparathyroidism secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Mazia Fatima (talk | contribs) No edit summary |
Mazia Fatima (talk | contribs) |
||
| Line 7: | Line 7: | ||
Secondary prevention measures in pseudohypoparathyroidism include:<ref name="pmid22736772">{{cite journal |vauthors=Neary NM, El-Maouche D, Hopkins R, Libutti SK, Moses AM, Weinstein LS |title=Development and treatment of tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1B |journal=J. Clin. Endocrinol. Metab. |volume=97 |issue=9 |pages=3025–30 |year=2012 |pmid=22736772 |pmc=3431579 |doi=10.1210/jc.2012-1655 |url=}}</ref> | Secondary prevention measures in pseudohypoparathyroidism include:<ref name="pmid22736772">{{cite journal |vauthors=Neary NM, El-Maouche D, Hopkins R, Libutti SK, Moses AM, Weinstein LS |title=Development and treatment of tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1B |journal=J. Clin. Endocrinol. Metab. |volume=97 |issue=9 |pages=3025–30 |year=2012 |pmid=22736772 |pmc=3431579 |doi=10.1210/jc.2012-1655 |url=}}</ref> | ||
* Monitor therapy with regular serum and urinary [[calcium]] measurements | * Monitor therapy with regular serum and urinary [[calcium]] measurements | ||
* Pseudohypoparathyroidism type 1b patients at an increased risk of developing [[hyperparathyroidism]] and [[hyperparathyroid]] bone disease should be maintained at sufficient doses of [[calcium]] and [[vitamin D]] to maintain serum [[calcium]] and [[PTH]] levels within the normal range | * Pseudohypoparathyroidism type 1b patients at an increased risk of developing [[hyperparathyroidism]] and [[hyperparathyroid]] bone disease should be maintained at sufficient doses of [[calcium]] and [[vitamin D]] to maintain serum [[calcium]] and [[PTH]] levels within the normal range. | ||
==References== | ==References== | ||
Latest revision as of 21:13, 17 October 2017
|
Pseudohypoparathyroidism Microchapters |
|
Differentiating Pseudohypoparathyroidism from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Pseudohypoparathyroidism secondary prevention On the Web |
|
American Roentgen Ray Society Images of Pseudohypoparathyroidism secondary prevention |
|
Risk calculators and risk factors for Pseudohypoparathyroidism secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]
Overview
Secondary prevention of measures in pseudohypoparathyroidism include regular serum and urinary calcium measurements monitoring.
Secondary Prevention
Secondary prevention measures in pseudohypoparathyroidism include:[1]
- Monitor therapy with regular serum and urinary calcium measurements
- Pseudohypoparathyroidism type 1b patients at an increased risk of developing hyperparathyroidism and hyperparathyroid bone disease should be maintained at sufficient doses of calcium and vitamin D to maintain serum calcium and PTH levels within the normal range.
References
- ↑ Neary NM, El-Maouche D, Hopkins R, Libutti SK, Moses AM, Weinstein LS (2012). "Development and treatment of tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1B". J. Clin. Endocrinol. Metab. 97 (9): 3025–30. doi:10.1210/jc.2012-1655. PMC 3431579. PMID 22736772.